Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ.

Clin Cancer Res. 2010 Feb 15;16(4):1298-306. doi: 10.1158/1078-0432.CCR-09-2469. Epub 2010 Feb 9.

2.

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, Fusco N, Adams R, Redline R, Faulhaber P, Dowlati A.

Gynecol Oncol. 2013 Jul;130(1):75-80. doi: 10.1016/j.ygyno.2013.04.019. Epub 2013 Apr 18.

3.

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.

Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, Sznol M.

Cancer Chemother Pharmacol. 2004 Oct;54(4):331-42. Epub 2004 May 18.

PMID:
15148626
4.

A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.

Martínez-Monge R, Gaztañaga M, Aramendía JM, Cambeiro M, Arbea L, Espinós J, Aristu JJ, Jurado M.

Int J Gynecol Cancer. 2010 Jan;20(1):133-40. doi: 10.1111/IGC.0b013e3181c057ff.

PMID:
20130514
5.
6.

Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.

Kunos C, Radivoyevitch T, Abdul-Karim FW, Fanning J, Abulafia O, Bonebrake AJ, Usha L.

J Transl Med. 2012 Apr 27;10:79. doi: 10.1186/1479-5876-10-79.

7.

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.

Mackenzie MJ, Saltman D, Hirte H, Low J, Johnson C, Pond G, Moore MJ.

Invest New Drugs. 2007 Dec;25(6):553-8. Epub 2007 Jun 22.

PMID:
17585372
8.

Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.

Kunos CA, Radivoyevitch T, Pink J, Chiu SM, Stefan T, Jacobberger J, Kinsella TJ.

Radiat Res. 2010 Nov;174(5):574-81. doi: 10.1667/RR2273.1. Epub 2010 Sep 10.

9.

Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.

Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Fleming GF.

Gynecol Oncol. 2004 Mar;92(3):801-5.

PMID:
14984944
10.
11.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y.

Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22.

12.

Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women.

Chumworathayi B, Yuenyao P, Tangvorapongchai V, Luanratanakorn S, Pattamadilok J, Krusun S.

Radiat Med. 2007 Nov;25(9):474-9. Epub 2007 Nov 26.

PMID:
18026906
13.

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ.

Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1.

PMID:
18977518
14.

Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.

Kunos CA, Colussi VC, Pink J, Radivoyevitch T, Oleinick NL.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1198-204. doi: 10.1016/j.ijrobp.2011.01.034. Epub 2011 Apr 4.

15.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

16.

Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.

Puget Sound Oncology Consortium., Swisher EM, Swensen RE, Greer B, Tamimi H, Goff BA, Garcia R, Koh WJ.

Gynecol Oncol. 2006 Jun;101(3):429-35. Epub 2005 Dec 9.

PMID:
16337995
17.

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.

Gynecol Oncol. 2005 Jan;96(1):168-72.

PMID:
15589596
18.

Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Ocean AJ, Christos P, Sparano JA, Matulich D, Kaubish A, Siegel A, Sung M, Ward MM, Hamel N, Espinoza-Delgado I, Yen Y, Lane ME.

Cancer Chemother Pharmacol. 2011 Aug;68(2):379-88. doi: 10.1007/s00280-010-1481-z. Epub 2010 Oct 28.

19.

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.

Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P, Almassian B, Colacino E, Fischer J, MacDonald S.

Cancer Chemother Pharmacol. 2002 Sep;50(3):223-9. Epub 2002 Aug 1.

PMID:
12203104
20.

Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.

DiSilvestro PA, Walker JL, Morrison A, Rose PG, Homesley H, Warshal D; Gynecologic Oncology Group..

Gynecol Oncol. 2006 Dec;103(3):1038-42. Epub 2006 Aug 4.

PMID:
16889823

Supplemental Content

Support Center